Scripps Research Logo

Laurent Mosnier, Ph.D.

Associate Professor
Department of Molecular Medicine
California Campus
Scripps VIVO Scientific Profile
lmosnier@scripps.edu
(858) 784-2227

Education

Ph.D. (Thrombosis and Hemostasis), Utrecht University 2001
B.B.A. (Economics), Erasmus University 1999
M.S. (Medical Biology), Utrecht University 1997
B.S. (Medical Biology), Utrecht University 1992

Professional Experience

2005-2017 Assistant Professor, Molecular and Experimental Medicine (MEM), The Scripps Research Institute

Selected References

All Publications

Griffin, J. H., Mosnier, L. O., Fernandez, J. A. & Zlokovic, B. V. 2016 Scientific Sessions Sol Sherry Distinguished Lecturer in Thrombosis. Thrombotic stroke: neuroprotective therapy by recombinant-activated protein C. (2016). Arteriosclerosis Thrombosis and Vascular Biology, 36(11), 2143-2151. PMCID: PMC5119536.

Wyseure, T., Mosnier, L. O. & von Drygalski, A. Advances and challenges in hemophilic arthropathy. (2016). Seminars in Hematology, 53(1), 10-19. PMCID: PMC5034876.

Sinha, R. K., Yang, X. V., Fernandez, J. A., Xu, X., Mosnier, L. O. & Griffin, J. H. Apolipoprotein E receptor 2 mediates activated protein C-induced endothelial Akt activation and endothelial barrier stabilization. (2016). Arteriosclerosis Thrombosis and Vascular Biology, 36(3), 518-524. PMCID: PMC4816599.

Cramer, T. J., Anderson, K., Navaz, K., Brown, J. M., Mosnier, L. O. & von Drygalski, A. Heterozygous congenital Factor VII deficiency with the 9729de14 mutation, associated with severe spontaneous intracranial bleeding in an adolescent male. (2016). Blood Cells Molecules and Diseases, 57, 8. PMCID: PMC4874642.

Bhat, V., von Drygalski, A., Gale, A. J., Griffin, J. H. & Mosnier, L. O. Improved coagulation and haemostasis in haemophilia with inhibitors by combinations of superFactor Va and Factor VIIa. (2016). Thrombosis and Haemostasis, 115(3), 551-561. PMCID: PMC4775351.

Gale, A. J., Bhat, V., Pellequer, J. L., Griffin, J. H., Mosnier, L. O. & Von Drygalski, A. Safety, stability and pharmacokinetic properties of (super)Factor Va, a novel engineered coagulation Factor V for treatment of severe bleeding. (2016). Pharmaceutical Research, 33(6), 1517-1526. PMCID: PMC4854778.

Mosnier, L. O. & Lavstsen, T. The role of EPCR in the pathogenesis of severe malaria. (2016). Thrombosis Research, 141, S46.

Griffin, J. H., Zlokovic, B. V. & Mosnier, L. O. Activated protein C: biased for translation. (2015). Blood, 125(19), 2898-2907. PMCID: PMC4424414.

Bouwens, E. A. M., Stavenuiter, F. & Mosnier, L. O. Cell painting with an engineered EPCR to augment the protein C system. (2015). Thrombosis and Haemostasis, 114(6), 1144-1155.

Petersen, J. E. V., Bouwens, E. A. M., Tamayo, I., Turner, L., Wang, C. W., Stins, M., Theander, T. G., Hermida, J., Mosnier, L. O. & Lavstsen, T. Protein C system defects inflicted by the malaria parasite protein PfEMP1 can be overcome by a soluble EPCR variant. (2015). Thrombosis and Haemostasis, 114(5), 1038-1048.